T(11;14)(q23;q32) involving IGH and DDX6 in nodal marginal zone lymphoma

Genes Chromosomes and Cancer

Volumn 52, Issue 1, 2013, Pages 33-43

  Stary, Susanne ^a   Vinatzer, Ursula ^a   Müllauer, Leonhard ^a   Raderer, Markus ^a   Birner, Peter ^a   Streubel, Berthold ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6; SMALL INTERFERING RNA;

ARTICLE; CHROMOSOME 12Q; CHROMOSOME 1Q; CHROMOSOME 8Q; CHROMOSOME ANALYSIS; CHROMOSOME WALKING; CLINICAL ARTICLE; CONTROLLED STUDY; DDX6 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE INTERACTION; GENE SILENCING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IGH GENE; MICROARRAY ANALYSIS; NODAL MARGINAL ZONE LYMPHOMA; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION;

CASPASES; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; CYTOGENETIC ANALYSIS; DEAD-BOX RNA HELICASES; DNA COPY NUMBER VARIATIONS; DNA-BINDING PROTEINS; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; LOSS OF HETEROZYGOSITY; LYMPHOMA, B-CELL, MARGINAL ZONE; NEOPLASM PROTEINS; NF-KAPPA B; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 84869864992     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22004     Document Type: Article

References (44)

1. Akao Y, Seto M, Takahashi T, Kubonishi I, Miyoshi I, Nakazawa S, Tsujimoto Y, Croce CM, Ueda R. 1991. Molecular cloning of the chromosomal breakpoint of a B-cell lymphoma with the t(11;14)(q23;q32) translocation. Cancer Res 51: 1574-1576.
2. Albers M, Kranz H, Kober I, Kaiser C, Klink M, Suckow J, Kern R, Koegl M. 2005. Automated yeast two-hybrid screening for nuclear receptor-interacting proteins. Mol Cell Proteomics 4: 205-213.
3. Arcaini L, Lucioni M, Boveri E, Paulli M. 2009. Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease. Eur J Haematol 83: 165-174.
4. Asirvatham AJ, Gregorie CJ, Hu Z, Magner WJ, Tomasi TB. 2008. MicroRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components. Mol Immunol 45: 1995-2006.
5. Baens M, Finalet Ferreiro J, Tousseyn T, Urbankova H, Michaux L, de Leval L, Dierickx D, Wolter P, Sagaert X, Vandenberghe P, De Wolf-Peeters C, Wlodarska I. 2012. t(X;14)(p11.4;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34. Haematologica 97: 184-188.
6. Basso K, Dalla-Favera R. 2010. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv Immunol 105: 193-210.
7. Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA, Salles G, Callet-Bauchu E, Coiffier B. 2000. Non-MALT marginal zone B-cell lymphomas: A description of clinical presentation and outcome in 124 patients. Blood 95: 1950-1956.
8. Brynes RK, Almaguer PD, Leathery KE, McCourty A, Arber DA, Medeiros LJ, Nathwani BN. 1996. Numerical cytogenetic abnormalities of chromosomes 3, 7, and 12 in marginal zone B-cell lymphomas. Mod Pathol 9: 995-1000.
9. Camacho FI, Algara P, Mollejo M, Garcia JF, Montalban C, Martinez N, Sanchez-Beato M, Piris MA. 2003. Nodal marginal zone lymphoma: A heterogeneous tumor: a comprehensive analysis of a series of 27 cases. Am J Surg Pathol 27: 762-771.
10. Cho H, Kim KM, Kim YK. 2009. Human proline-rich nuclear receptor coregulatory protein 2 mediates an interaction between mRNA surveillance machinery and decapping complex. Mol Cell 33: 75-86.
11. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, Pasqualucci L. 2009. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459: 717-721.
12. Dierlamm J, Rosenberg C, Stul M, Pittaluga S, Wlodarska I, Michaux L, Dehaen M, Verhoef G, Thomas J, de Kelver W, Bakker-Schut T, Cassiman JJ, Raap AK, De Wolf-Peeters C, Van den Berghe H, Hagemeijer A. 1997. Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization. Leukemia 11: 747-758.
13. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, De Wolf-Peeters C, Hagemeijer A, Van den Berghe H, Marynen P. 1999. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93: 3601-3609.
14. Farinha P, Gascoyne RD. 2005. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 23: 6370-6378.
15. Gilmore T, Gapuzan ME, Kalaitzidis D, Starczynowski D. 2002. Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer. Cancer Lett 181: 1-9.
16. Iida S, Saito M, Okazaki T, Seto M, Yamamoto K, Akao Y, Ogura M, Suzuki H, Ariyoshi Y, Koike K, et al. 1992. Phenotypic and genotypic characterization of 14 leukemia and lymphoma cell lines with 11q23 translocations. Leuk Res 16: 1155-1163.
17. Kalaitzidis D, Davis RE, Rosenwald A, Staudt LM, Gilmore TD. 2002a. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappaB signal transduction pathway. Oncogene 21: 8759-8768.
18. Kalaitzidis D, Gilmore TD. 2002b. Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8. Genes Chromosomes Cancer 34: 129-135.
19. Korn JM, Kuruvilla FG, McCarroll SA, Wysoker A, Nemesh J, Cawley S, Hubbell E, Veitch J, Collins PJ, Darvishi K, Lee C, Nizzari MM, Gabriel SB, Purcell S, Daly MJ, Altshuler D. 2008. Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat Genet 40: 1253-1260.
20. Kubonishi I, Niiya K, Miyoshi I. 1985. Establishment of a new human lymphoma line that secretes plasminogen activator. Jpn J Cancer Res 76: 12-15.
21. Kubonishi I, Niiya K, Yamashita M, Yano S, Abe T, Ohtsuki Y, Miyoshi I. 1986. Characterization of a new human lymphoma cell line (RC-K8) with t(11;14) chromosome abnormality. Cancer 58: 1453-1460.
22. Leisser C, Rosenberger G, Maier S, Fuhrmann G, Grusch M, Strasser S, Huettenbrenner S, Fassl S, Polgar D, Krieger S, Cerni C, Hofer-Warbinek R, deMartin R, Krupitza G. 2004. Subcellular localisation of Cdc25A determines cell fate. Cell Death Differ 1: 80-89.
23. Madlener S, Rosner M, Krieger S, Giessrigl B, Gridling M, Vo TP, Leisser C, Lackner A, Raab I, Grusch M, Hengstschlager M, Dolznig H, Krupitza G. 2009. Short 42 degrees C heat shock induces phosphorylation and degradation of Cdc25A which depends on p38MAPK, Chk2 and 14.3.3. Hum Mol Genet 18: 1990-2000.
24. Matsui T, Hogetsu K, Usukura J, Sato T, Kumasaka T, Akao Y, Tanaka N. 2006. Structural insight of human DEAD-box protein rck/p54 into its substrate recognition with conformational changes. Genes Cells 11: 439-452.
25. Minshall N, Kress M, Weil D, Standart N. 2009. Role of p54 RNA helicase activity and its C-terminal domain in translational repression, P-body localization and assembly. Mol Biol Cell 20: 2464-2472.
26. Nathwani BN, Anderson JR, Armitage JO, Cavalli F, Diebold J, Drachenberg MR, Harris NL, MacLennan KA, Muller-Hermelink HK, Ullrich FA, Weisenburger DD. 1999. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 17: 2486-2492.
27. Nonhoff U, Ralser M, Welzel F, Piccini I, Balzereit D, Yaspo ML, Lehrach H, Krobitsch S. 2007. Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol Biol Cell 18: 1385-1396.
28. Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM, Compagno M, Cerri M, Rossi D, Murty VV, Zucca E, Gaidano G, Dalla-Favera R, Pasqualucci L, Bhagat G, Bertoni F. 2009. The NF-{kappa{B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 113: 4918-4921.
29. Sagaert X, De Wolf-Peeters C, Noels H, Baens M. 2007. The pathogenesis of MALT lymphomas: Where do we stand? Leukemia 21: 389-396.
30. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA. 2006. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435-443.
31. Saito M, Novak U, Piovan E, Basso K, Sumazin P, Schneider C, Crespo M, Shen Q, Bhagat G, Califano A, Chadburn A, Pasqualucci L, Dalla-Favera R. 2009. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci USA 106: 11294-11299.
32. Salido M, Baro C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L, Espinet B, Luno E, Wlodarska I, Verhoef G, Garcia-Granero M, Salar A, Papadaki T, Serrano S, Piris MA, Sole F. 2010. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood 116: 1479-1488.
33. Streubel B, Lamprecht A, Dierlamm J, Cerroni L, Stolte M, Ott G, Raderer M, Chott A. 2003. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 101: 2335-2339.
34. Streubel B, Simonitsch-Klupp I, Mullauer L, Lamprecht A, Huber D, Siebert R, Stolte M, Trautinger F, Lukas J, Puspok A, Formanek M, Assanasen T, Muller-Hermelink HK, Cerroni L, Raderer M, Chott A. 2004. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 18: 1722-1726.
35. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. 2005. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 19: 652-658.
36. Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press.
37. Traverse-Glehen A, Felman P, Callet-Bauchu E, Gazzo S, Baseggio L, Bryon PA, Thieblemont C, Coiffier B, Salles G, Berger F. 2006. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology 48: 162-173.
38. Tritschler F, Braun JE, Eulalio A, Truffault V, Izaurralde E, Weichenrieder O. 2009. Structural basis for the mutually exclusive anchoring of P body components EDC3 and Tral to the DEAD box protein DDX6/Me31B. Mol Cell 33: 661-668.
39. Vinatzer U, Gollinger M, Mullauer L, Raderer M, Chott A, Streubel B. 2008. Mucosa-associated lymphoid tissue lymphoma: Novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin Cancer Res 14: 6426-6431.
40. Wotherspoon AC, Diss TC, Pan LX, Schmid C, Kerr-Muir MG, Lea SH, Isaacson PG. 1993. Primary low-grade B-cell lymphoma of the conjunctiva: A mucosa-associated lymphoid tissue type lymphoma. Histopathology 23: 417-424.
41. Zhou D, Chen S. 2001. PNRC2 is a 16 kDa coactivator that interacts with nuclear receptors through an SH3-binding motif. Nucleic Acids Res 29: 3939-3948.
42. Zhou D, Quach KM, Yang C, Lee SY, Pohajdak B, Chen S. 2000. PNRC: A proline-rich nuclear receptor coregulatory protein that modulates transcriptional activation of multiple nuclear receptors including orphan receptors SF1 (steroidogenic factor 1) and ERRalpha1 (estrogen related receptor alpha-1). Mol Endocrinol 14: 986-998.
43. Zhou Y, Ye H, Martin-Subero JI, Hamoudi R, Lu YJ, Wang R, Siebert R, Shipley J, Isaacson PG, Dogan A, Du MQ. 2006. Distinct comparative genomic hybridisation profiles in gastric mucosa-associated lymphoid tissue lymphomas with and without t(11;18)(q21;q21). Br J Haematol 133: 35-42.
44. Zhou Y, Ye H, Martin-Subero JI, Gesk S, Hamoudi R, Lu YJ, Wang R, Shipley J, Siebert R, Isaacson PG, Dogan A, Du MQ. 2007. The pattern of genomic gains in salivary gland MALT lymphomas. Haematologica 92: 921-927.